摘要
目的评价门冬胰岛素联合地特胰岛素与门冬胰岛素30对新诊断2型糖尿病患者的有效性和安全性。方法选择96例新诊断的2型糖尿病患者,分别使用门冬胰岛素联合地特胰岛素(A组,50例)和门冬胰岛素30(B组,46例)强化治疗方案,观察治疗前后的静脉空腹血糖(fasting plasma glucose,FPG)、FPG达标率、静脉餐后2h血糖(2hour postprandial plasma glucose,2hPG)、2hPG达标率、糖化血红蛋白(glycated hemoglobin,HbAlc)、HbAlc达标率、低血糖发生率、体质量增加情况。结果治疗12w后,两组患者的FPG、2hPG、HbAlc均较基线显著降低,两组FPG、2hPG及2hPG达标率、HbAlc和HbAlc达标率差异均无统计学意义,但A组FPG达标率高于B组(P<0.05);两组低血糖发生率分别为21.3%、25.1%,B组有可记录到的夜间低血糖发生。A组患者治疗前后体质指数(body mass index,BMI)无明显变化,B组患者治疗后BMI有所增加,但差异无统计学意义。结论门冬胰岛素联合地特胰岛素与门冬胰岛素30强化治疗,均可以安全有效地控制患者的血糖,在控制夜间低血糖发生和体质量增加方面,门冬胰岛素联合地特胰岛素方案可能更具优势。
Objective To evaluate the efficacy and safety of insulin aspart combined with insulin detemir and insulin aspart 30 on newly diagnosed type 2 diabetic patients. Methods 96 newly diagnosed type 2 diabetic patients were divided randomly into two groups： group A （n =50） treated by insulin aspart before three meals combined with insulin detemir before bedtime; group B （n = 46） by insulin aspart 30 before three meals. FPG, FPG target arrival rate, 2 hPG, 2 hPG target arrival rate, HbAlc, HbAlc target arrival rate, hypoglycemia, weight gain were observed at the baseline and the end of the trail. Results After 12 weeks treatment, the level of FPG, 2 hPG, HbAlc decreased significantly form baseline in two groups, and there were no difference of FPG, 2 hPG, 2 hPG target arrival rate, HbAlc, HbAlc target arrival rate between two groups. But FPG target arrival rate was higher in group A. The incidence of hypoglycemia in two groups was 21.3G and 25.1% respectively, and it happened hypoglycemia at nighttime in group B. here was no weigh gain after treatment in group A, while a little weigh gain in group B without statistic fference. Conclusion In newly diagnosed type 2 diabetic patients, treatment with insulin aspart comned with insulin detemir and insulin aspart 30 both would improve blood glucose control effectively and safely, there were more advantage of hypoglycemia at nighttime and weight gain in group A.
出处
《新疆医科大学学报》
CAS
2013年第6期802-804,共3页
Journal of Xinjiang Medical University
基金
新疆维吾尔自治区自然科学基金(2012211A067)
